Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-11-01
2005-11-01
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S290000, C514S387000, C514S397000, C544S234000, C546S101000, C548S302100, C548S311400, C548S311700, C548S304400
Reexamination Certificate
active
06960586
ABSTRACT:
The present invention provides a compound having a steroid C17,20-lyase inhibitory activity, which is useful as a prophylactic or therapeutic agent of prostatism and tumor such as breast cancer and the like.A compound represented by the formula:wherein R is a hydrogen atom or a protecting group, R1is a lower alkyl group or a cyclic alkyl group, and ring A and ring B are each an optionally substituted 5-membered or 6-membered ring having an amide bond in the ring, or a salt thereof.
REFERENCES:
patent: 5491161 (1996-02-01), Janssen et al.
patent: 0260744 (1988-03-01), None
patent: 0288053 (1988-10-01), None
patent: 0413270 (1991-02-01), None
patent: 0721943 (1996-07-01), None
patent: 0974584 (2000-01-01), None
patent: 1028110 (2000-08-01), None
patent: WO 92/15404 (1992-09-01), None
patent: WO 92/15604 (1992-09-01), None
patent: WO 94/27989 (1994-12-01), None
patent: WO 96/14090 (1996-05-01), None
patent: WO 97/00257 (1997-01-01), None
patent: WO 93/20097 (1998-10-01), None
patent: WO 99/54309 (1999-10-01), None
Njar and Brodie, “Inhibitors of 17alpha-Hydroxylase/17,20-Lyase (CYP17): Potential Agents for the Treatment of Prostate Cancer” Current Pharmaceutical Design, vol. 5, pp. 163-180 (1990).
Beckmann et al. “Multistep carcinogenesis of breast cancer and tumour heterogeneity” Journal of Molecular Medicine, vol. 75(6 pp. 429-439 (1997).
Al-Dabbagh and Smith, “Species differences in oxidative drug metabolism: some basic considerations.” Archives of toxicology. Supplement. Archiv fur Toxikologie. supplement, vol. 7, pp. 219-231 (1984).
Hans Bundgaard, Design of Prodrugs, p. 1. © 1985 Elsevier Science Publishers.
Richard B. Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-400. © 1992 Academic Press, Inc.
Ingvarsson, “Molecular genetics of breast cancer progression” Seminars in Cancer Biology, vol. 9, pp. 277-288 (1999).
Wachall, et al. “Imidazole Substituted Biphenyls: A New Class of Highly Potent and In Vivo Active Inhibitors of P450 17 as Potential Therapeutics for Treatment of Prostate Cancer” Bioorganic & Medicinal Chemistry 7:1913-1924 (1999).
Zhuang, et al. “Novel Imidazolyl and Triazolyl Substituted Biphenyl Compounds: Synthesis and Evaluation as Nonsteroidal Inhibitors of Human 17 α-Hydroxylase-C17, 20-Lyase (P450 17)” Bioorganic & Medicinal Chemistry 8: 1245-1252 (2000).
Kusaka Masami
Matsunaga Nobuyuki
Ojida Akio
Tasaka Akihiro
Chao Mark
Ramesh Elaine M.
Takeda Pharmaceutical Company Limited
Tucker Zachary C.
Wilson James O.
LandOfFree
Imidazole derivatives, process for their preparation and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazole derivatives, process for their preparation and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazole derivatives, process for their preparation and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3494003